Cell freezing media market seen reaching $3 billion by 2030

The cell freezing media market is projected to grow from $1.77 billion in 2025 to $3 billion by 2030 as biobanking, stem cell research and cell and gene therapy expand. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Cell freezing media supports long-term storage of living cells used in research, therapies and diagnostics. - Faster growth in cell and gene therapy, personalized medicine and biobanking is increasing demand for reliable cryopreservation products. - The market’s projected climb to $3 billion by 2030 points to steady spending on storage infrastructure and preservation technology.

What happened: - The Business Research Company said the global cell freezing media market reached $1.77 billion in 2025 and is expected to rise to $1.97 billion in 2026. - The market is forecast to reach $3 billion by 2030, implying an 11.0% CAGR from 2026 to 2030. - The report cites strong recent expansion tied to biotechnology advances and higher demand for cell preservation solutions. - The company released the findings in its Cell Freezing Media Global Market Report 2026, covering market size, trends and a forecast through 2035. - The report is available as a full market report, and a free sample is also offered.

The details: - The market’s earlier growth was driven by biobanking initiatives, wider use of cryopreservation in research and expansion of stem cell research programs. - The report also points to broader adoption of controlled-rate freezing technologies and improved liquid nitrogen storage infrastructure. - Cell freezing media is formulated to preserve cells at ultra-low temperatures, often in liquid nitrogen, while maintaining viability and functional integrity. - The media typically includes cryoprotective agents that help prevent ice crystal formation during freezing and thawing. - The product is used to support long-term storage of biological samples for research, therapeutic treatments and diagnostic applications. - Future growth is expected to come from rising use of large-scale cell banking, personalized medicine research, stricter storage-quality rules and automated cryopreservation systems. - The report highlights trends toward ready-to-use cryopreservation media, serum-free freezing solutions, GMP-grade cryoprotectants, longer-term cell banking and better post-thaw recovery. - In February 2024, the Personalized Medicine Coalition said the U.S. Food and Drug Administration approved 26 personalized medicines in 2023, up from 12 in 2022.

Between the lines: - Personalized medicine is becoming a larger driver because patient-specific treatments depend on preserving cells and biological materials with consistent quality. - The shift toward automated and GMP-grade solutions suggests the market is moving from basic storage toward more regulated, scalable and standardized workflows. - North America’s leadership reflects advanced biotech infrastructure and heavy research activity, while Asia-Pacific’s growth outlook tracks expanding healthcare systems and government support.

What's next: - The report expects demand to keep rising as cell and gene therapy pipelines expand and more organizations build large-scale cell banks. - Asia-Pacific is projected to be the fastest-growing regional market over the coming years. - The report’s additional tools include TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and updated graphics and tables. - The company also lists contact details for its expert team and social channels for follow-up inquiries.